title: First Report of Ceftazidime-Avibactam Resistance in a KPC-3-Expressing Klebsiella pneumoniae Isolate.
abstract: Ceftazidime-avibactam is the first antimicrobial approved by the U.S. FDA for the treatment of carbapenem-resistant Enterobacteriaceae. Avibactam, a non-β-lactam β-lactamase inhibitor, inactivates class A serine carbapenemases, including Klebsiella pneumoniae carbapenemase (KPC). We report a KPC-producing K. pneumoniae isolate resistant to ceftazidime-avibactam (MIC, 32/4 μg/ml) from a patient with no prior treatment with ceftazidime-avibactam.
authors.affiliation: Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA rhumphries@mednet.ucla.edu jfhindler@mednet.ucla.edu.
authors.forename: Romney M
authors.initials: RM
authors.lastname: Humphries
authors.affiliation: Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: Shangxin
authors.initials: S
authors.lastname: Yang
authors.affiliation: Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: Peera
authors.initials: P
authors.lastname: Hemarajata
authors.affiliation: Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: Kevin W
authors.initials: KW
authors.lastname: Ward
authors.affiliation: Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA rhumphries@mednet.ucla.edu jfhindler@mednet.ucla.edu.
authors.forename: Janet A
authors.initials: JA
authors.lastname: Hindler
authors.affiliation: Department of Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: Shelley A
authors.initials: SA
authors.lastname: Miller
authors.affiliation: Department of Medicine, Division of Infectious Diseases, University of California, Los Angeles, Los Angeles, California, USA.
authors.forename: Aric
authors.initials: A
authors.lastname: Gregson
mesh_terms: D053961:Azabicyclo Compounds / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000378:metabolism*; D002442:Ceftazidime / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial; D007711:Klebsiella pneumoniae / Q000187:drug effects / Q000201:enzymology*; D008826:Microbial Sensitivity Tests; D065093:beta-Lactamase Inhibitors / Q000494:pharmacology*; D001618:beta-Lactamases / Q000378:metabolism*
chemical_list: D053961:Azabicyclo Compounds; D001426:Bacterial Proteins; D065093:beta-Lactamase Inhibitors; C543519:avibactam; D002442:Ceftazidime; D001618:beta-Lactamases; C495220:beta-lactamase KPC-3, Klebsiella pneumoniae